Table 1.
Patient characteristics
| Parameter (n = 105 patients) | Descriptive statistic | |
|---|---|---|
| Age, year | 67 ± 15 | [29, 97] |
| Sex | ||
| Male | 58 (55.2) | |
| Female | 47 (44.8) | |
| Body mass index, kg/m2 | 29.6 ± 6.3 | [17.1, 48.7] |
| Race/ethnicity | ||
| Hispanic | 33 (31.4) | |
| Non-Hispanic White | 12 (11.4) | |
| Non-Hispanic Black | 43 (40.9) | |
| Non-Hispanic Asian | 3 (2.9) | |
| Non-Hispanic Other | 6 (5.7) | |
| Unknown | 8 (7.6) | |
| Comorbidities | ||
| Hypertension | 51 (48.6) | |
| Diabetes mellitus | 41 (39.0) | |
| Cardiomyopathy | 6 (5.7) | |
| Prior MI | 5 (4.8) | |
| Chronic kidney disease | 30 (28.6) | |
| Prior atrial fibrillation | 20 (19.0) | |
| Other QT prolonging agents during hospitalization1 | ||
| Class I antiarrhythmics | 0 (0.0) | |
| Class III antiarrhythmics2 | 5 (4.8) | |
| Ondansetron | 11 (10.5) | |
| Methadone | 3 (2.9) | |
| Ejection fraction, % (most recent if available) | 58.7 ± 10.5 | [30, 80] |
| Treatment | ||
| Chloroquine | 5 (4.8) | |
| Hydroxychloroquine | 40 (38.1) | |
| Azithromycin | 21 (20.0) | |
| Chloroquine and hydroxychloroquine | 1 (1.0) | |
| Chloroquine and azithromycin | 4 (3.8) | |
| Hydroxychloroquine and azithromycin | 33 (31.4) | |
| Chloroquine, hydroxychloroquine, and azithromycin | 1 (1.0) | |
| Intubated | 34 (32.4) | |
| Mortality | 29 (27.6) | |
Reported as mean ± SD or n (%). Ranges reported for continuous variables
1Recorded if medication was administered between pre- and post‑medication ECG
21 patient on dofetilide and 4 patients on amiodarone